Clinical & Experimental Immunology · 2014 · 15 citations · 48 references
Life SciencesEndocrinologyImmunologyAutoimmunityImmunopathologyInflammationAutoimmune Disease PathogenesisAutoimmune Disease PathologyAutoimmune DiseasesAutoimmune EndocrinopathiesGenetic Susceptibility To AutoimmunityInterferon ResponsesAdrenal Cortex FunctionAutoimmune Addison DiseaseAutoimmune Endocrine DiseaseImmunopathological MechanismsInterferon-gamma ResponsesInterferon-mediated PathologyType I Interferon InductionType I Interferon Signature
Autoimmune Addison's disease (AAD) is caused by selective destruction of the hormone-producing cells of the adrenal cortex. As yet, little is known about the potential role played by environmental factors in this process. Type I and/or type III interferons (IFNs) are signature responses to virus infections, and have also been implicated in the pathogenesis of autoimmune endocrine disorders such as type 1 diabetes and autoimmune thyroiditis. Transient development of AAD and exacerbation of established or subclinical disease, as well as the induction of autoantibodies associated with AAD, have been reported following therapeutic administration of type I IFNs. We therefore hypothesize that exposure to such IFNs could render the adrenal cortex susceptible to autoimmune attack in genetically predisposed individuals. In this study, we investigated possible immunopathological effects of type I and type III IFNs on adrenocortical cells in relation to AAD. Both types I and III IFNs exerted significant cytotoxicity on NCI-H295R adrenocortical carcinoma cells and potentiated IFN-γ- and polyinosine-polycytidylic acid [poly (I : C)]-induced chemokine secretion. Furthermore, we observed increased expression of human leucocyte antigen (HLA) class I molecules and up-regulation of 21-hydroxylase, the primary antigenic target in AAD. We propose that these combined effects could serve to initiate or aggravate an ongoing autoimmune response against the adrenal cortex in AAD.
48
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Lena Alexopoulou, Agnieszka Czopik Holt, Ruslan Medzhitov et al. · Nature · 2001 · 6.1K citations
IL-28, IL-29 and their class II cytokine receptor IL-28R
Paul O. Sheppard, Wayne Kindsvogel, Wenfeng Xu et al. · Nature Immunology · 2002 · 1.6K citations